MAPT and early-onset autosomal dominant Alzheimer disease: In addition to superior enhancement of cognitive performance and restoration of neurotransmitter balance, S/L treatment more effectively reduced oxidative stress and neuroinflammatory indices and robustly downregulated Alzheimer’s disease–specific biomarkers, including BACE1, Aβ, and p-Tau.